2013年4月1日 · The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Oancea C et al 15362364

2012年11月16日 · Translocation t (6;9) is a rare recurring cytogenetic aberration resulting in the formation of a chimeric fusion gene, DEK-NUP214 (previously known as DEK-CAN) that occurs in <2% of adult or pediatric AML. This translocation has been reported in AML and less frequently in myelodysplastic syndrome and Ph-negative chronic myeloid leukemia.

急性髓系白血病伴t(6;9)(p23;q34.1); DEK-NUP214在形态学上可表现为单核或非单核分化特征，常伴有噬碱粒细胞增多和多系异形。 诊断要点： 发病率占AML的不到2%，儿童和成人都可发病。

t(6;9)(p22;q34.1)/DEK-NUP214 is a recurrent genetic abnormality that occurs in 1–2% of patients with acute myeloid leukemia (AML), and rarely in myelodysplastic syndrome (MDS).

急性髓系白血病伴t(6:9)(p23:q34)-dek-nup214基因重排是一种发生率较低、恶性度高、化疗反应低、复发风险高、容易漏诊和较难进行鉴别诊断，需结合该 ...

目的 探讨伴t (6;9) (p23;q34)急性髓细胞白血病 (acute myeloid leukemia,AML)患者的临床和生物学特点.方法 抽取骨髓细胞按常规制备染色体标本,采用R显带技术进行核型分析;采用标准流式细胞仪和一组单抗检测白血病细胞的抗原表达;应用6号与9号全染色体涂染探针进行染色体荧光原位杂交 (fluorescence in situ hybridization,FISH)分析;应用逆转录-PCR技术进行DEK/CAN融合基因和FLT3-ITD突变的检测.结果 t (6;9)易位主要见于M2和M4 (M2 4例,M4 2例).所有病例的原始细胞 …

患者以发热、皮下结节为临床表现，结合骨髓细胞形态学、免疫学、遗传学、分子生物学检查，诊断为AML-M 2a 伴t（6；9），基因检测提示DEK-CAN、TP53、DNMT3A、ASXL1、TET2、FLT3-ITD均阳性。 患者对常规化疗无效，因合并严重肺部感染而接受维奈克拉联合阿扎胞苷治疗获得完全缓解，患者家属拒绝行异基因造血干胞移植，错过最佳治疗时机，原发病复发后最终放弃治疗。 伴t（6；9）AML治疗难度大，预后极差，常规化疗无效时维奈克拉联合阿扎胞苷治疗 …

Acute myelogenous leukemia (AML) with chromosomal translocation (6;9) (p23;q34) is a rare disease with poor prognosis and distinct clinical and morphologic features. t (6;9) results in a chimeric fusion gene between DEK (6p23) and CAN/NUP214 (9q34).

结论：伴有t（6；9）核型畸变的AML是一类独特的预后极差的白血病，经典的IA或DA方案化疗效果差，有效的治疗方案有待进一步研究。 为了探讨伴有核型畸变t（6；9）（p23；q34）急性髓系白血病（AML）的特性，本研究对11例此类疾病患者的实验室及临床资料进行了回顾性分析，包括免疫表型分析和实时荧光定量PCR检测结果分析。

2010年12月1日 · Among patients with acute myeloid leukemia (AML), the t(6;9) (p22;q34) is a rare but defined subset with a poor prognosis. We report 16 patients with the t(6;9), of whom 13 had AML, 2 had myelodysplastic syndrome (MDS), and 1 had chronic myeloid leukemia in myeloid blast crisis (CML-BC).